Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| 12/31/2024 | 09/30/2024 | 02/29/2024 | 11/30/2023 | 08/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 493.10K | -- | -- |
| Gross Profit | -- | -- | -493.10K | -- | -- |
| SG&A Expenses | -- | -- | 1.84M | 1.77M | 1.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 2.86M | 3.01M | 3.51M |
| Operating Income | -- | -- | -2.86M | -3.01M | -3.51M |
| Income Before Tax | -- | -- | -3.51M | -3.55M | -3.92M |
| Income Tax Expenses | -- | -- | 1.70K | 1.70K | 1.70K |
| Earnings from Continuing Operations | -- | -- | -3.52 | -3.56 | -3.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -3.52M | -3.56M | -3.92M |
| EBIT | -- | -- | -2.86M | -3.01M | -3.51M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | -0.04 | -0.04 | -0.04 |
| Normalized Basic EPS | -- | -- | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -- | -- | -0.04 | -0.04 | -0.04 |
| Normalized Diluted EPS | -- | -- | -0.02 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | -- | -- | 373.50M | 367.41M | 361.33M |
| Average Diluted Shares Outstanding | -- | -- | 373.50M | 367.41M | 361.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
